Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Denton

Showing results (391-400 of 484) with videos related to

Pageof 49
Sort By:
Rheumatology (Oxford, England)|September 22, 2018
European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosisGiuseppina Abignano, Jelena Blagojevic, Lesley-Anne Bissell, et al.
The American Journal of Pathology|June 14, 2013
Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosisXiaoyan Tang, Ruoqi Peng, Jonathan E Phillips, et al.
Rheumatology (Oxford, England)|January 31, 2024
A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud'sGöran Tornling, Charlotte Edenius, John D Pauling, et al.
Autoimmunity Reviews|September 15, 2019
Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern"Vanessa Smith, Amber Vanhaecke, Ariane L Herrick, et al.
Seminars in Arthritis and Rheumatism|October 12, 2023
Surgical management of digital ulcers in systemic sclerosis: A systematic literature reviewYossra A Suliman, Corrado Campochiaro, Michael Hughes, et al.
Clinical Rheumatology|January 10, 2020
Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung diseaseCarmel J W Stock, Angelo De Lauretis, Dina Visca, et al.
Arthritis Research & Therapy|September 2, 2025
Transforming growth factor beta (TGF-β) induces type 1 interferon signalling in systemic sclerosis keratinocytes through the chloride intracellular channel 4 (CLIC4)Christopher W Wasson, Sophie L Dibb, Begoña Caballero-Ruiz, et al.
Annals of the Rheumatic Diseases|May 1, 2020
Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient managementMarco Matucci-Cerinic, Cosimo Bruni, Yannick Allanore, et al.
Journal of Scleroderma and Related Disorders|June 19, 2026
Expert recommendations for the management of fecal incontinence in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee"Zsuzsanna H McMahan, Maria Cristina De Santis, Anna Lo Cricchio, et al.
Chest|December 15, 2025
Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical PracticeAnthony J Esposito, Kavitha C Selvan, Carrie Richardson, et al.
Pageof 49

Showing results (391-400 of 484) with videos related to

Sort By:
Pageof 49
Rheumatology (Oxford, England)|September 22, 2018
European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosisGiuseppina Abignano, Jelena Blagojevic, Lesley-Anne Bissell, et al.
The American Journal of Pathology|June 14, 2013
Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosisXiaoyan Tang, Ruoqi Peng, Jonathan E Phillips, et al.
Rheumatology (Oxford, England)|January 31, 2024
A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud'sGöran Tornling, Charlotte Edenius, John D Pauling, et al.
Autoimmunity Reviews|September 15, 2019
Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern"Vanessa Smith, Amber Vanhaecke, Ariane L Herrick, et al.
Seminars in Arthritis and Rheumatism|October 12, 2023
Surgical management of digital ulcers in systemic sclerosis: A systematic literature reviewYossra A Suliman, Corrado Campochiaro, Michael Hughes, et al.
Clinical Rheumatology|January 10, 2020
Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung diseaseCarmel J W Stock, Angelo De Lauretis, Dina Visca, et al.
Arthritis Research & Therapy|September 2, 2025
Transforming growth factor beta (TGF-β) induces type 1 interferon signalling in systemic sclerosis keratinocytes through the chloride intracellular channel 4 (CLIC4)Christopher W Wasson, Sophie L Dibb, Begoña Caballero-Ruiz, et al.
Annals of the Rheumatic Diseases|May 1, 2020
Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient managementMarco Matucci-Cerinic, Cosimo Bruni, Yannick Allanore, et al.
Journal of Scleroderma and Related Disorders|June 19, 2026
Expert recommendations for the management of fecal incontinence in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee"Zsuzsanna H McMahan, Maria Cristina De Santis, Anna Lo Cricchio, et al.
Chest|December 15, 2025
Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical PracticeAnthony J Esposito, Kavitha C Selvan, Carrie Richardson, et al.
Pageof 49